Thus far, the anticancer property of several NK1R antagonists has been tested in different glioblastoma-derived cell lines and xenograft models; however, efforts are still underway to find a drug that has maximal tumor suppressor activity and minimal side effects. Here, TACR1 is linked to glioblastoma.